Protocol Ledger

NCT04038502 · Phase II · RECRUITING

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Interventional Phase II clinical trial protocol NCT04038502 sponsored by VA Office of Research and Development in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-01 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04038502
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04038502
Protocol FieldVerified Registry Value
NCT IdentifierNCT04038502
Consolidated Lead SponsorVA Office of Research and Development
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2019-10-01
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI